- Home
- CAPR vs DGICB Comparison
CAPR vs DGICB Comparison
Compare CAPR & DGICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- DGICB
- Stock Information
- Founded
- CAPR 2005
- DGICB 1986
- Country
- CAPR United States
- DGICB United States
- Employees
- CAPR N/A
- DGICB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- DGICB Property-Casualty Insurers
- Sector
- CAPR Health Care
- DGICB Finance
- Exchange
- CAPR Nasdaq
- DGICB Nasdaq
- Market Cap
- CAPR 578.4M
- DGICB 504.0M
- IPO Year
- CAPR N/A
- DGICB N/A
- Fundamental
- Price
- CAPR $14.06
- DGICB $14.50
- Analyst Decision
- CAPR Strong Buy
- DGICB
- Analyst Count
- CAPR 7
- DGICB 0
- Target Price
- CAPR $39.29
- DGICB N/A
- AVG Volume (30 Days)
- CAPR 1.1M
- DGICB 805.0
- Earning Date
- CAPR 02-27-2025
- DGICB 02-20-2025
- Dividend Yield
- CAPR N/A
- DGICB 4.28%
- EPS Growth
- CAPR N/A
- DGICB 148.60
- EPS
- CAPR N/A
- DGICB 0.74
- Revenue
- CAPR $23,228,045.00
- DGICB $979,119,004.00
- Revenue This Year
- CAPR N/A
- DGICB N/A
- Revenue Next Year
- CAPR $74.85
- DGICB $5.78
- P/E Ratio
- CAPR N/A
- DGICB $19.93
- Revenue Growth
- CAPR 65.33
- DGICB 7.44
- 52 Week Low
- CAPR $3.52
- DGICB $10.75
- 52 Week High
- CAPR $23.40
- DGICB $16.81
- Technical
- Relative Strength Index (RSI)
- CAPR 48.54
- DGICB 51.57
- Support Level
- CAPR $12.31
- DGICB $13.53
- Resistance Level
- CAPR $16.17
- DGICB $14.88
- Average True Range (ATR)
- CAPR 0.82
- DGICB 0.22
- MACD
- CAPR 0.11
- DGICB 0.02
- Stochastic Oscillator
- CAPR 45.34
- DGICB 47.08
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About DGICB Donegal Group Inc. Class B
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.